

## Power of Contemporary Clinical Strategies to Detect Patients with Obstructive Coronary Artery Disease

Ruben Ramos\*, Pedro Rio, Tiago Pereira - da - Silva, Carlos Barbosa, Duarte Cacela, António Fiarresga, Lídia de Sousa, Ana Abreu, Lino Patrício, Luís Bernardes and Rui Cruz Ferreira

Department of Cardiology, Hospital de Santa Marta, Lisboa, Portugal

### Abstract

**Background:** Non-invasive Ischemia Testing (NIST) is recommended for most patients suspected to have stable coronary artery disease (CAD) before invasive cardiac angiography (ICA). We sought to assess the diagnostic predictive ability of NIST over clinical risk profiling in a contemporary sample of patients undergoing the currently recommended diagnostic triage strategy.

**Methods and results:** From 2006 - 2011, 2600 consecutive patients without known CAD undergoing elective ICA in a single tertiary - care centre were retrospectively identified and the prevalence of obstructive CAD determined. To understand the incremental value of frequently used clinical parameters in predicting obstructive CAD, receiver - operating - characteristic curves were plotted for six sequential models starting with Framingham risk score and then progressively adding multiple clinical factors and finally NIST results.

At ICA 1268 patients (48.8%) had obstructive. The vast majority (85%) were classified in an intermediate clinical pre - test probability of CAD and NIST prior to ICA was used in 86% of the cohort. The most powerful correlate of obstructive CAD was the presence of severe angina (OR = 9.1, 95% confidence interval (CI), 4.3 - 19.1). Accordingly, the incorporation of NIST in a sequential model had no significant effect on the predictive ability over that achieved by clinical and symptomatic status model (C - statistic 0.754; 95% CI, 0.732 - 0.776,  $p = 0.28$ ).

**Conclusions:** Less than half the patients with suspect stable obstructive CAD referred to a tertiary level centre for elective ICA had the diagnosis confirmed. In this clinical setting, the results of NIST may not have the power to change the discriminative ability over clinical judgment alone.

**Keywords:** Angiography; Coronary disease; Diagnosis

### Introduction

It is estimated that care for Coronary Artery Disease (CAD) results in annual direct and indirect costs of around 50€ billion within the European Union [1]. A sizable proportion of this expenditure results from procedures used with the sole intention to confirm the diagnosis. Invasive coronary angiography (ICA) is still the gold standard for establishing the presence of CAD. Despite some variations in the diagnostic workflow among international guidelines, most algorithms usually recommend Noninvasive Ischemia Testing (NIST) before referral for ICA in stable patients with low to intermediate risk [2,3]. Accordingly, use of NIST has grown substantially in recent years [4]. However, it is unknown whether this strategy contributes incrementally to diagnostic efficiency. A contemporary observational study from the United States comprising almost 400,000 patients submitted to ICA found that even for those with prior positive NIST, the diagnostic yield of ICA for obstructive CAD was only 41% [5]. It is acknowledged, however, that there may be significant populational and geographic variation on this figure ranging from 33 to 73% of obstructive CAD [1,5,6]. This discrepancy may reflect not only different baseline risk of the studied population but also the diagnostic strategy used. Nonetheless, it is estimated that each year, in the European Union, about 400,000 patients undergo unnecessary ICA [1].

We sought to perform a clinical audit to determine the diagnostic yield of ICA in a tertiary centre from Western Europe. We used a sample of patients following the usual risk stratification strategy based on clinical judgment complemented with NIST. We also assessed the incremental diagnostic predictive ability of NIST over clinical risk profiling alone.

### Methods

#### Patient selection


This was a retrospective, cross - sectional study performed at a single public hospital from January 2006 through December 2011. All data was entered prospectively into the departmental patient information system (SIGUS, Cardiology Department - Central Lisbon Medical Center) and retrospectively analyzed. Consecutive patients with suspected stable CAD (with or without a previous NIST) who were referred for their first elective ICA were included (Figure 1). Therefore, patients with known heart disease (documented coronary stenosis  $\geq 50\%$  on previous ICA, previous myocardial infarction, percutaneous coronary intervention, coronary-artery bypass surgery, or undergoing ICA as routine workup before cardiac non - coronary surgery were excluded, as were patients with indications for emergency or urgent cardiac catheterization (acute coronary syndromes, cardiogenic shock or life - threatening ventricular dysrhythmia). The study protocol conforms to the ethical guidelines of the Declaration of Helsinki.

\*Corresponding author: Ruben Ramos, Cardiology Service, Hospital de Santa Marta, 1169-024, Rua de Santa Marta 50, Lisboa, Portugal, Tel: 00351-963156910; Fax: 00351-213560368; E-mail: [ruben.a.b.ramos@gmail.com](mailto:ruben.a.b.ramos@gmail.com)

Received May 21, 2015; Accepted December 14, 2015; Published January 01, 2016

**Citation:** Ramos R, Rio P, da Silva TP, Barbosa C, Cacela D, et al. (2016) Power of Contemporary Clinical Strategies to Detect Patients with Obstructive Coronary Artery Disease. J Vasc Med Surg 4: 243. doi:10.4172/2329-6925.1000243

**Copyright:** © 2016 Ramos R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



## Patient evaluation

Data on demographic characteristics, classic and non-classic CAD risk factors [including peripheral artery disease (PAD), chronic obstructive pulmonary disease (COPD), cerebrovascular disease (CVD) and renal dysfunction (CKD)], symptomatic status, type and results of NIST as well as the results of the first ICA performed in the study period were prospectively collected. Symptomatic status was categorized as non - anginal symptoms; atypical chest pain (including dyspnea, fatigue or equivalent); typical angina. Pre - test probability for CAD was retrospectively calculated using an update Diamond-Forrester classification [7]. Intermediate probability was arbitrarily defined as pre - test risk between 15 - 85% of ischemic heart disease. The modalities of NIST routinely used were Exercise Treadmill Test (ETT) and stress myocardial Single-Photon Emission Computed Tomography (SPECT). Only tests performed before the ICA were considered. The results were categorized as positive, negative, or equivocal. Degree of positivity of the NIST results was not considered. Information on Left Ventricular Systolic Function (LVSF) was considered whenever available. For patients with more than one LVSF assessment method, the preferred method was nuclear ventriculography, after echocardiography and

finally was invasive ventriculography. Normal LVSF was defined as LV ejection fraction >55%. A modified Framingham risk score [8] was calculated for non - diabetic individuals on the basis of available clinical data, with a moderate score (i.e., 1 point) imputed for either a history of dyslipidemia or the use of statins and for the presence of hypertension or a history of medication use for the treatment of high blood pressure.

## ICA

Interpretation of ICA was based on visual assessment only. No quantitative coronary angiogram was performed and data from intracoronary imaging, like fractional flow reserve, intravascular ultrasound or optical coherence tomography, were not considered. Obstructive CAD was defined as stenosis  $\geq$  50% of the left main coronary artery or stenosis  $\geq$  70% of a major epicardial vessel or branch vessel with at least 1.5 mm in diameter. Normal coronary artery was defined as complete absence of any luminal narrowing detectable by angiography. Non - obstructive CAD was defined as CAD not meeting the criteria for obstructive CAD or normal coronary arteries.

## Statistical analysis

We determined the rate of obstructive CAD in the overall

population and also according to clinical pre - test probabilities and results of NIST. In order to identify variables associated with obstructive CAD, the population was divided in two groups, patients with and without obstructive CAD. We compared the baseline demographic characteristics, cardiovascular risk factors, symptoms, and results of NIST between the groups. Normally distributed continuous variables were compared using Student's *t* tests and are expressed as mean  $\pm$  SD; continuous variables not normally distributed were compared using Mann - Whitney tests and are expressed as medians and interquartile ranges. Variables that showed association with obstructive CAD in univariate analysis ( $p < 0.10$ ) were included in a multivariate logistic regression model to identify independent correlates ( $p < 0.05$ ).

To study the incremental value of different parameters in predicting obstructive CAD, a stepwise (6 steps) logistic regression analysis was carried out, starting with FRS alone and then sequentially adding; non - classical risk factors; symptomatic status; pre - test probability of CAD; left ventricular systolic function; and NIST result. The receiver - operating - characteristic (ROC) curves of each model were compared using a nonparametric method [9]. *P* - value of less than .05 was considered statistically significant. All data were analyzed using SPSS 16.0.

## Results

### Study population

The study population consisted of 2600 patients with suspected CAD who were undergoing their first elective ICA, 13.6% of which without any previous NIST. This final cohort represented 47.6% of a total of 5458 ICA procedures performed during the 7 years of the study period. Reasons for patients exclusion were known history of heart

disease in 1590 (29.1%), urgent ICA indication in 1193 (21.9%), and other reasons such as routine workup based on institutional defined protocols in 75 (1.3%) patients (Figure 1).

### Prevalence of obstructive CAD

The prevalence of obstructive CAD was 48.8% ( $n = 1268$ ). Normal coronary arteries as defined per protocol were found in 1035 (39.8%) patients and the remaining represents patients with non - obstructive CAD (10.4%). Multivessel disease was present in 735 patients representing 58% of all obstructive CAD and 28.3% of the entire population. Left main and/or 3 vessel - disease was present in 323 patients (12.4% of the entire population).

### Demographic and clinical characteristics

Detailed population characteristics are described in Table 1. In general, the study cohort consisted of a predominantly male population (60%), with a low (5.7%) prevalence of associated comorbidities. Except for COPD and CKD, all traditional and non - traditional cardiovascular risk factors were significantly associated with presence of obstructive CAD in univariate analysis (Table 2). One third of the cohort had no anginal symptoms but was sent for ICA due perceived high risk, high FRS and/or a positive NIST. Most patients (85.1%) were classified in an intermediate clinical pre - test probability of ischemic heart disease. Patients with low and high pre - test probabilities represented 3.4% and 11.5% of the whole population, respectively. Typical symptoms of angina were present in half the population and were also significantly associated with obstructive CAD. After adjustment however, only severe symptoms (CCS 3 or 4) was independently associated with obstructive CAD (OR 9.1, 95% CI 4.33 - 19.1).

Characteristic	Total (N = 2600)	Obstructive Coronary Artery Disease (N=1268)	No Obstructive Coronary Artery Disease (N=1332)	P Value
Age (yr)	65 $\pm$ 9.9	67 $\pm$ 9.7	64 $\pm$ 9.8	<0.001
Female sex (%)	1057 (40.7)	374 (29.5)	683 (51.3)	<0.001
<b>Clinical risk factors</b>				
Body-mass index	28.2 $\pm$ 4.3	28.0 $\pm$ 4.1	28.4 $\pm$ 4.4	0.035
History of smoke (%)	461 (17.7)	272 (21.5)	189 (14.2)	<0.001
Current (%)	229 (8.8)	134 (10.6)	95 (7.1)	0.001
Diabetes (%)	704 (27.1)	409 (32.3)	295 (22.1)	<0.001
Hypertension (%)	1933 (74.3)	971 (76.6)	962 (72.2)	0.012
Dyslipidemia (%)	1603 (61.7)	825 (65.1)	778 (58.4)	0.001
Peripheral vascular disease (%)	53 (2.0)	38 (3.0)	15 (1.1)	0.001
Cerebrovascular disease (%)	48 (1.8)	34 (2.7)	14 (1.1)	0.001
Chronic obstructive pulmonary disease (%)	29 (1.1)	18 (1.4)	11 (0.8)	0.19
Chronic kidney disease (%)	20 (0.85)	13 (1)	7 (0.5)	0.18
Framingham risk score (?)				<0.001
Low (<10%) (%)	771 (29.7)	288 (22.7)	483 (36.3)	
Intermediate (%)	1064 (40.9)	525 (41.4)	539 (40.5)	
High (>20%) (%)	765 (29.4)	455 (35.9)	310 (23.3)	
LV systolic dysfunction (%)	241 (11.1)	169 (16.3)	72 (6.3)	<0.001
Clinical status				<0.001
No angina (%)	868 (33.4)	332 (26.1)	536 (40.2)	
Atypical angina (%)	435 (16.7)	52 (4.1)	383 (28.8)	
Stable angina (%)	1297 (49.9)	884 (69.7)	413 (31.0)	
Clinical pre-test probability	55.6 $\pm$ 24.1	66.0 $\pm$ 21.3	45.8 $\pm$ 22.5	<0.001
Low (<15%) (%)	89 (3.4)	11 (0.9)	78 (5.9)	
Intermediate (%)	2213 (85.1)	1028 (81.1)	1185 (89)	
High (>85%) (%)	298 (11.5)	229 (18.1)	69 (5.2)	

Table 1: Population characteristics.

Variable	Odds Ratio	CI (95%)	P value
Age, per 5-yr increase	1.16	1.12 - 1.21	<0.001
Male sex	2.52	2.14 - 2.96	<0.001
Body-mass index, per 5-unit increase	0.91	0.83 - 0.99	0.033
History of smoke	1.65	1.35 - 2.03	<0.001
Diabetes	1.67	1.41 - 1.99	<0.001
Hypertension	1.26	1.05 - 1.50	0.011
Dyslipidemia	1.33	1.13 - 1.55	<0.001
High Framingham risk score	1.85	1.56 - 2.19	<0.001
Peripheral vascular disease	2.71	1.49 - 4.96	0.001
Cerebrovascular disease	2.59	1.39 - 4.86	0.003
Left ventricular dysfunction	2.88	2.15 - 3.84	<0.001
<b>Clinical status</b>			
Atypical angina	0.10	0.08 - 0.14	<0.001
Stable angina	5.64	4.74 - 6.71	<0.001
CCS* Class 3 or 4	5.19	3.18 - 8.47	<0.001
High clinical pre-test probability	4.03	3.05 - 5.35	<0.001
<b>Noninvasive stress test</b>			
Positive result	1.85	1.33 - 2.58	<0.001
Equivocal result	0.5	0.36 - 0.69	<0.001

\*Canadian Cardiovascular Society

Table 2: Predictors of Obstructive Coronary Artery Disease, univariate analysis.

### Noninvasive ischemia test and LV systolic function

From the 2600 patients included, the vast majority (86.4%) had at least one NIST prior to ICA. Considering that ischemia testing would be justified only in patients in an intermediate pre - test risk category, then a NIST was appropriately used in 73.4% of the whole population. ETT was the single test performed in 1201 (46.2%), SPECT only in 782 (30.1%) and 262 patients (10.1%) had both. Only 2 patients in the low risk category did not receive a previous NIST. Likelihood of receiving a NIST before ICA was not significantly different in the intermediate and high - risk categories (86.4 vs 82.6%, respectively,  $p = 0.08$ ). Ninety three percent of patients had a positive result in at least one NIST.

Inconclusive and negative results in one or both tests were found in 5% and 2%, respectively. Rate of obstructive CAD did not differ after a patient has made a SPECT or an ETT (47.2% and 46.3%, respectively,  $p = 0.68$ ). Also, rate of obstructive CAD did not differ after a positive SPECT or ETT (49.0% and 48.4%, respectively,  $p = 0.83$ ). Figure 2 shows the rate of obstructive CAD according to pre - test likelihood and NIST results. As expected, there was a progressive increase in the rate of obstructive CAD from low to high pre - test likelihood. Interestingly though, in the intermediate risk category where a NIST is usually considered necessary, observed rate of obstructive CAD did not differ significantly for those with positive or negative NIST (47% vs. 43% respectively,  $p = 0.66$ ). Equivalent rates of obstructive CAD were also found in the high pre test risk category, when patients with positive NIST were compared to those with no previous NIST (77.6 vs 78.8%).

For 262 patients ETT and SPECT were used sequentially and both tests resulted positive for ischemia in 47%. The prevalence of obstructive CAD was not significantly different when only one NIST resulted positive versus both positive 43.4% and 49.4%, ( $p = 0.23$ ).

An assessment of LV systolic function was available for analysis in 2170 patients (83.4% of the study population). From these patients, normal LVSF was found in 89% and moderate to severe LV systolic dysfunction was present in 3.3%. Prevalence of obstructive CAD in patients with any degree of LV systolic dysfunction was 70.1%.

### Correlates of obstructive CAD

Increasing age, male sex, history of smoke, diabetes, left ventricular dysfunction, and severe angina were independent correlates of obstructive CAD (Table 3). A positive NIST were associated with obstructive CAD in univariate analysis, but after adjustment this association was no longer significant (OR 1.69 95% CI 0.952 - 3.09). The strongest correlate of obstructive CAD was the presence of severe angina (class 3 or 4 of Canadian Cardiovascular Society (CCS)) (OR = 9.1 95% CI 4.3 - 19.1), left ventricular systolic dysfunction (OR = 3.3 95% CI 1.7 - 6.3) and male sex (OR = 3.04 95% CI 2.09 - 4.44).




Figure 2: Prevalence of obstructive coronary artery disease, according to clinical pre-test probability and noninvasive test results.



Variable	Wald Chi-Square Statistic	Adjusted Odds Ratio	CI (95%)	P value
Age, per 5-yr increase	9.91	1.12	1.06 - 1.30	0.002
Male sex	33.47	3.04	2.09 - 4.44	<0.001
Body-mass index, per 5-unit increase	6.94	0.79	0.66 - 0.94	0.008
History of smoke	4.68	1.62	1.05 - 2.52	0.031
Diabetes	9.59	1.74	1.23 - 2.47	0.002
Left ventricular dysfunction	12.91	3.30	1.72 - 6.33	<0.001
Clinical status				
CCS* Class 3 or 4	33.85	9.10	4.33 - 19.15	<0.001

\*Canadian Cardiovascular Society

**Table 3:** Predictors of Obstructive Coronary Artery Disease, multivariate analysis.

A stepwise analysis was performed to study the incremental value of different parameters in predicting obstructive CAD (Figure 3). Predictive power of each model is given by the C - statistic value over a 95%CI. The first model included only a modified Framingham risk score as initial approach for general CV risk assessment irrespective of symptomatic status (0.595, 0.569 - 0.620). In the second model, non - classical risk factors and comorbidities such as PAD, CVD, CKD and COPD were added. The C - statistic for this model remained unchanged (0.601, 0.576 - 0.627). With the incorporation of the symptomatic status there was a significant increase in the model's predictive ability (0.735, 0.712 - 0.758  $p < 0.001$ ). When we added the pretest probability (obtained by the Diamond - Forrester method) no change was noted. In the fifth step, inclusion of the LVSF caused a slight, albeit not significant ( $p = 0.29$ ), increase in the predictive ability (0.751, 0.729 - 0.773). Finally, the sixth step consisted in the addition of the noninvasive ischemia test results, which had no significant effect on the model's predictive ability over that already achieved by previous steps (0.754, 0.732 - 0.776,  $p = 0.28$ ).

## Discussion


In this study including 2600 patients with suspected CAD undergoing their first elective ICA in a single tertiary care, urban and

public european centre, the rate of obstructive CAD was 48.8%. This occurred despite appropriate use (but not necessarily interpretation) of non - invasive stress tests in more than 70% of the patients.

The incidence of obstructive CAD as diagnosed by ICA in elective patients has been suggested as a health care performance measure [9] and the 2013 catheterization and percutaneous coronary intervention standards from the Accreditation for Cardiovascular Excellence organization suggests this figure should be above 60% [10]. However, strategies to achieve this goal are not simple. Most international guidelines, largely based on prognostic reasons, suggests that patient in pre - test intermediate risk category should be selected for ICA according to NIST results [2,3]. However, despite geographic and temporal variations in the rate of no obstructive disease after ICA, most contemporary studies using NIST strategies for patient selection fail to show success in increasing the yield of ICA. Genders [11] in a multicenter study involving 11 European hospitals reported a rate of obstructive CAD of 58% (ranging from 39.4% to 75.5%). Patel [5] in the USA reported a rate of 37.6% of obstructive CAD among patients those who undergone elective ICA in the National Cardiovascular Data Registry. There was however a wide regional variation among the hospital referral regions, from 23 to 100% [12].

Several factors may influence the diagnostic performance of ICA. The increased availability and more liberal use of ICA may be one explanation. The 30 year - old Coronary Artery Surgery Study (CASS) [13] with more than twenty thousand angiograms showed 81% of patients with obstructive CAD. This is in contrast with the more recent data from registries showing that this rate is between 38 to 50% [14]. Even though this may suggest a temporal decrease in ICA yield, it is difficult to draw definite conclusions since past studies included patients with varying cut points to define obstructive CAD, with previous myocardial infarction or revascularization procedures, urgent indications and some failed to report on the used non invasive ischemia test strategy, if any.

Also, the impact of NIST on the ICA performance is not entirely clear. A recent published study [4] suggests that despite the increasing



**Figure 3:** Predictive power of each model to detect obstructive CAD is given by the area under the curve (AUC). The only significant increment was observed when symptoms were added to baseline clinical risk.

availability of noninvasive tests through the years, the proportion of patients with normal coronary arteries or undergoing revascularization remains unchanged. One of the often pointed reasons for this is the overall low pre - test probability of obstructive CAD in the studied population. In our cohort more than 85% fell in the intermediate risk category and thus a NIST would be considered appropriately indicated. Germane to this discussion is not just the appropriate indication for NIST but also the appropriate interpretation of the results. Notwithstanding the fact that NIST have intrinsic accuracy and referral strategy limitations, there may be several other factors driving use of ICA after NIST. These may include the role of the patients, family, and colleagues' expectations, fear of liability and, importantly, a feeling, albeit debatable, that prognostic risk stratification is not complete until the coronary anatomy is known [15-18]. If we are to take this last factor into account, coronary computed tomography angiography (CCTA) may have an important role [19-23]. The ongoing ISCHEMIA trial is evaluating the best management strategy for patients with stable ischemic heart disease. Most patients are required to undergo CCTA before randomization both to confirm the presence obstructive CAD and to exclude LM disease. Preliminary results (after enrolling 1078 patients), have found that even for these high - risk patients with core - lab adjudicated moderate to severe ischemia, 13.6% were found to have no obstructive CAD [24]. Even though these findings may represent true flow limitation due to small vessel disease or endothelial dysfunction, it illustrates the thesis that even in an optimal environment, patient selection based on NIST may not be sufficient to increase the diagnostic yield of ICA.

In this study we also sought to determine factors associated with the presence of obstructive CAD as defined by ICA. Demographic and symptom characteristics are generally used to estimate pre-test risk of CAD based on clinical risk assessment models [15,16]. The original populations from which these data were derived as well as the validation cohort data used are now over 30 years old and were obtained before the current wide availability of ICA. Thus, it is acknowledged that risk assessment in these stratification models may be now overestimated at least in primary care setting [17]. Nonetheless, our data confirms that typical angina was the strongest independent predictive factors for obstructive CAD followed by other traditional risk factors such as older age, male sex, use of tobacco, diabetes, as well as presence of abnormal LV systolic function. In fact, in our stepwise construct, the only significant increment in the ability to predict obstructive CAD was observed when symptomatic status was considered (increase in AUC from 0.60 - 0.74). Moreover, use of NIST did not significantly add predictive power over demography and symptoms, especially when LV systolic function was also considered (AUC change from 0.73 - 0.74). This remained true irrespective of Framingham baseline risk (data not shown).

These observations suggest that there is room for improvement and better strategies for patient stratification, before undergoing to ICA, are desirable. The incremental value of NIST is limited and therefore other methods of functional and/or anatomic assessment to increase the yield of ICA are necessary [19-23]. Finally, in this era of increasing use and even dependence on medical technology our study shows that careful history taking for the accurate elucidation of symptoms, especially typical angina should not be overlooked in the evaluation of patients with CAD.

## Limitations

First, this is a retrospective analysis. It is possible that there might

have been variables used by clinicians to direct patients for ICA namely rest ECG abnormalities, non classified symptoms or other hidden confounders not reflected in pretest risk estimation or NIST results. Also, Framingham risk score (FRS) may be underestimated because in our database dyslipidemia and hypertension are classified as categorical variables and therefore a modified FRS was used using imputed values for lipid levels and blood pressure. Second, patients were subjected to referral bias. This analysis was focused exclusively in patients referred for ICA. Thus, we have no data on subjects evaluated for presence of CAD that for any reason did not receive ICA. Therefore, we could not determine the incremental value of NIST in confirming CAD diagnosis but we could not determine the overall performance of the NIST, and most notably its ability to exclude CAD. Third, the database was not powered to provide information on details of NIST results. Information such as high risk features, extent or ischemia location or reason for equivocal results were not available. Fourth, even though data on symptomatic status was prospectively collected at the initial clinical interview, the database is also a clinical tool and thus it is susceptible to post test symptom reclassification bias. Hence, it is not unlikely that an initially designated typical angina would be reclassified as atypical or absent after an ICA showing normal epicardial coronaries, particularly if symptoms are inconsistent. Fourth, angiographic findings were not adjudicated and lesion severity assessment was based on operator's semi - quantitative angiographic classification. Also, we did not correlate ischemic territories with distribution of lesions in the coronary tree. Thus, lack of use of invasive fraction flow reserve in this cohort is a limitation given its demonstrated reclassification potential. Fifth, only ETT and SPECT were used so these results cannot be extrapolated to other functional tests such as stress echocardiography or magnetic resonance imaging. Sixth, although we used a standard definition of obstructive CAD (stenosis >70%), often angiographically moderate stenosis, especially in long lesions, may be flow limiting.

## Conclusions

In this retrospective study, less than half the patients with suspect CAD referred to a tertiary level centre for elective ICA were found to have obstructive CAD. In this clinical setting, results of non invasive ischemia test did not have significant discriminative power over clinical judgment alone to predict obstructive coronary artery disease. Better strategies or tests need to be designed to improve the diagnostic yield of ICA.

## References

1. Mathers CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. *PLoS Med* 3: e442.
2. Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, et al. (2013) 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J* 34: 2949-3003.
3. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, et al. (2012) 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *Circulation* 126: e354-471.
4. Fröhlich GM, Schoch B, Wolfrum M, Osranek M, Enseleit F, et al. (2014) The impact of modern noninvasive cardiac imaging on coronary intervention rates. *J Interv Cardiol* 27: 50-57.
5. Patel MR, Peterson ED, Dai D, Brennan JM, Redberg RF, et al. (2010) Low diagnostic yield of elective coronary angiography. *N Engl J Med* 362: 886-895.

6. Shaw LJ, Mieres JH, Hendel RH, Boden WE, Gulati M, et al. (2011) Comparative effectiveness of exercise electrocardiography with or without myocardial perfusion single photon computed tomography in women with suspected coronary artery disease: results from the What Is the Optimal Method for Ischemia Evaluation in Women (WOMEN) trial. *Circulation* 124: 1239-1249.
7. <http://www.framinghamheartstudy.org/risk/coronary.html>
8. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics* 44: 837-845.
9. Bashore TM, Bates ER, Berger PB, Clark DA, Cusma JT, et al. (2001) American College of Cardiology/Society for Cardiac Angiography and Interventions Clinical Expert Consensus Document on cardiac catheterization laboratory standards: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol* 37: 2170-2214.
10. (2013) ACE Standards for Catheterization Laboratory Accreditation.
11. Genders TS, Steyerberg EW, Alkadhi H, Leschka S, Desbiolles L, et al. (2011) A clinical prediction rule for the diagnosis of coronary artery disease: validation, updating, and extension. *Eur Heart J* 32: 1316-1330.
12. Douglas PS, Patel MR, Bailey SR, Dai D, Kaltenbach L, et al. (2011) Hospital variability in the rate of finding obstructive coronary artery disease at elective, diagnostic coronary angiography. *J Am Coll Cardiol* 58: 801-809.
13. Kemp HG, Kronmal RA, Vlietstra RE, Frye RL (1986) Seven year survival of patients with normal or near normal coronary arteriograms: a CASS registry study. *J Am Coll Cardiol* 7: 479-483.
14. Lange RA, Hillis LD (1998) Use and overuse of angiography and revascularization for acute coronary syndromes. *N Engl J Med* 338: 1838-1839.
15. Diamond GA, Forrester JS (1979) Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. *N Engl J Med* 300: 1350-1358.
16. Pryor DB, Shaw L, McCants CB, Lee KL, Mark DB, et al. (1993) Value of the history and physical in identifying patients at increased risk for coronary artery disease. *Ann Intern Med* 118: 81-90.
17. Cheng VY, Berman DS, Rozanski A, Dunning AM, Achenbach S, et al. (2011) Performance of the traditional age, sex, and angina typicality-based approach for estimating pretest probability of angiographically significant coronary artery disease in patients undergoing coronary computed tomographic angiography: results from the Multinational Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry (CONFIRM). *Circulation* 124: 2423-2432.
18. Lucas FL, Sirovich BE, Gallagher PM, Siewers AE, Wennberg DE (2010) Variation in cardiologists' propensity to test and treat: is it associated with regional variation in utilization? *Circ Cardiovasc Qual Outcomes* 3: 253-260.
19. Greenwood JP, Maredia N, Younger JF, Brown JM, Nixon J, et al. (2012) Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. *Lancet* 379: 453-460.
20. Chinnaiyan KM, Raff GL, Goraya T, Ananthasubramaniam K, Gallagher MJ, et al. (2012) Coronary computed tomography angiography after stress testing: results from a multicenter, statewide registry, ACIC (Advanced Cardiovascular Imaging Consortium). *J Am Coll Cardiol* 59: 688-695.
21. de Graaf FR, van Velzen JE, de Boer SM, van Werkhoven JM, Kroft LJ, et al. (2013) Non-invasive computed tomography coronary angiography as a gatekeeper for invasive coronary angiography. *Int J Cardiovasc Imaging* 29: 221-228.
22. Patel N, Pal RS, Flores F, Budoff M (2012) Utility of Cardiac Computed Tomography Angiography to Exclude Clinically Significant Obstructive Coronary Artery Disease in Patients After Myocardial Perfusion Imaging. *Am J Cardiol* 109: 165-168.
23. Halpern EJ, Savage MP, Fischman DL, Levin DC (2010) Cost-effectiveness of coronary CT angiography in evaluation of patients without symptoms who have positive stress test results. *AJR Am J Roentgenol* 194: 1257-1262.
24. <https://clinicaltrials.gov/ct2/show/NCT01471522>